Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indonesia Rejects Complaints About New Drug Production Rule

This article was originally published in PharmAsia News

Executive Summary

Indonesia's health minister dismissed complaints about new rules requiring foreign drug makers to have a local production facility before they can sell in the country. Minister Siti Fadilah Supari said the intent of the new rules was to force the companies to invest in the country instead of taking advantage of its potential for sales. Thirteen multinational pharmaceuticals are affected by the rule since they market products in the country, but do not have a production facility in Indonesia. A U.S. business group complained about the rule that requires foreign pharmas to establish production facilities in Indonesia within two years or stop selling their products in the $2 billion-a-year market. Critics of the rule say it could lead to a lack of some life-saving drugs in Indonesia. (Click here for more
Advertisement

Related Content

Indonesia Decree Requiring Foreign Drug Makers To Build Local Plants “Disastrous”
Advertisement
UsernamePublicRestriction

Register

SC067351

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel